NCT05137158Completed
iTBS on Negative Symptoms and Cognitive Function in Schizophrenia
The Effect of Intermittent Theta Burst Stimulation on Negative Symptoms And Cognitive Function in Schizophrenia
Source: ClinicalTrials.gov · Last updated 20 Aug 2024
Brief summary (registry, in English)
The negative symptoms and cognitive deficits are common in patients with schizophrenia, and do not respond well to antipsychotics. The effective treatments for negative symptoms and cognitive impairment are still to be explored. rTMS is a safe and non-invasive physical treatment, some studies has been indicated that the high frequency rTMS could increase the excitability of cortex, and has potentials to improve negative symptoms and cognitive function in schizophrenia. In this study, we explore the effects of iTBS on negative symptoms and cognitive function based on identifying the brain network connection of schizophrenia symptoms.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 66 (actual)
- First submitted
- 9 Nov 2021
- Start date
- 15 Oct 2022
- Primary completion date
- 14 Jun 2024
- Lead sponsor
- Central South University
- Diseases
- Schizophrenia
- NCT number
- NCT05137158
What you commit to
- Study type: Interventional
- Participants enrolled: 66
- From 15 Oct 2022 to the primary completion date, 14 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drug or alcohol abuse
- Received rTMS or electroconvulsive therapy in the past 1 month
Other illness
- Diagnosed with other mental disease in accordance with DSM-5
- Combined with other severe physiological disease
Other
- Used antidepressants, mood stabilizer, or other psychoactive substances before
- Pregnant or lactating
- Contraindication to rTMS
Who the study is looking for
- Patients with schizophrenia in accordance with DSM-5
- The disease duration ≤8 years
- Received a steady dose of antipsychotic medication for least 4 weeks
- The Global Deficit Score of MCCB ≥0.5 or the PANSS negative subscore ≥20
- No obvious extrapyramidal side effects caused by antipsychotic drugs
- Informed Consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Second Xiangya Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.